Ascendis Pharma A/S 6-K Filing
Ticker: ASND · Form: 6-K · Filed: Dec 10, 2025 · CIK: 1612042
Sentiment: neutral
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 15.8 · Accepted 2025-12-10 16:15:00
Key Financial Figures
- $196.63 — y and has an exercise price equal to US $196.63 per share, the closing price of the Ame
Filing Documents
- d65335d6k.htm (6-K) — 13KB
- d65335dex11.htm (EX-1.1) — 1204KB
- g65335dsp174.jpg (GRAPHIC) — 3KB
- g65335dsp175.jpg (GRAPHIC) — 3KB
- g65335dsp177.jpg (GRAPHIC) — 3KB
- g65335dsp178.jpg (GRAPHIC) — 3KB
- g65335dsp179.jpg (GRAPHIC) — 3KB
- g65335dsp180.jpg (GRAPHIC) — 5KB
- g65335dsp_24a.jpg (GRAPHIC) — 4KB
- g65335dsp_25a.jpg (GRAPHIC) — 8KB
- g65335dsp_25b.jpg (GRAPHIC) — 3KB
- g65335dsp_26a.jpg (GRAPHIC) — 6KB
- g65335dsp_33a.jpg (GRAPHIC) — 4KB
- g65335dsp_33b.jpg (GRAPHIC) — 8KB
- g65335dsp_34a.jpg (GRAPHIC) — 3KB
- g65335dsp_34b.jpg (GRAPHIC) — 6KB
- g65335page43.jpg (GRAPHIC) — 4KB
- g65335page44a.jpg (GRAPHIC) — 8KB
- g65335page44b.jpg (GRAPHIC) — 3KB
- g65335page45.jpg (GRAPHIC) — 6KB
- 0001193125-25-314210.txt ( ) — 1338KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: December 10, 2025 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer